CRISPR experiment shows how butterflies get their coloring – Science Magazine
Science Magazine |
CRISPR experiment shows how butterflies get their coloring
Science Magazine As far as nature’s animal canvases go, the butterfly wing must rank somewhere near the top—maybe above the goldfish, but below the peacock. The level of complexity in the patterns and colors of the insects’ wings initially led scientists to believe … Mutant butterflies reveal the genetic roots of colorful wingsWashington Post CRISPR reveals genetic master switches behind butterfly wing patternsNature.com Butterfly wing patterns altered with CRISPR offer insights into evolution of biodiversityNew Atlas ZME Science –New York Times –New Scientist –Proceedings of the National Academy of Sciences all 18 news articles » |
Harvard Health |
Teaching T cells to fight cancer
Harvard Health One of the most innovative immunotherapies today is chimeric antigen receptor (CAR) T-cell therapy, which is custom-made for individuals and their specific cancer. “It can be an alternative for people who are resistant to chemotherapy, or diseases that … |
WJXT Jacksonville |
Video: Woman unable to receive stem cell transplant after government denies sister’s visa
WJXT Jacksonville Video: Woman unable to receive stem cell transplant after government denies sister’s visa. Posted: 3:58 PM, September 19, 2017 Updated: 4:10 PM, September 19, 2017. Headline Goes Here. KTLA. A California grandmother diagnosed with leukemia is … Vietnamese Stem Cell Donor Denied Entry to the US to Save Dying Sister from CancerNextShark |
|
Clinicians Devise Guidelines for Handling CAR T-Cell Side Effects
Managed Care magazine “CAR T cells provide an entirely new level of improved disease response among patients with certain blood cancers and hold promise for more wide-ranging use,” said Elizabeth Shpall, MD, deputy chair and professor of stem cell transplantation and … |
|
Gray Hair Turns Dark After Immunotherapy Treatment
www.oncnursingnews.com/ The study, which was published in JAMA Dermatology, examined 14 patients who have non–small cell lung cancer and were receiving immunotherapy treatments including nivolumab (Opdivo), pembrolizumab (Keytruda), or atezolizumab (Tecentriq) at a … |